Navigation Links
New Data Support Use of Simple Test to Predict Endometrial Cancer Response to Chemotherapy
Date:6/1/2009

Study Presented at 2009 American Society of Clinical Oncologist Annual Meeting

ORLANDO, Fla., June 1 /PRNewswire/ -- New data presented today at the 2009 American Society of Clinical Oncologist (ASCO) Annual Meeting support the use of a laboratory test, ChemoFX(R), to help physicians predetermine the effectiveness of chemotherapy in treating a woman's endometrial cancer. Investigators found a significant correlation between the test results from 405 patient specimens analyzed using ChemoFx and published patient response rates for each chemotherapeutic regimen, suggesting less effective therapies could be eliminated prior to patient administration. Endometrial cancer is the most common gynecologic cancer among women in the United States.

"Limiting a patient's exposure to chemotherapy is important, however determining the appropriate treatment the first time for a woman with endometrial cancer can be challenging," said Dr. Warner K. Huh, MD., Lead Investigator and Associate Professor, Division of Gynecologic Oncology, University of Alabama at Birmingham, "These data suggest a more targeted approach could be achieved by testing the effect of various chemotherapeutic agents on a woman's tumor before a therapy is administered to the patient, potentially bypassing use of ineffective therapies."

Published data suggest that individual patients will only respond to a single chemotherapy agent 30 percent of the time and while combination therapy can increase a patient's response up to 60 percent, finding the combination that will achieve that response can prove difficult. The unintended consequences of ineffective treatment include, but are not limited to, patient exposure to the toxic aspects of the chemotherapy and delay in the patient receiving potentially beneficial treatments. ChemoFx is a test that quantifies an individual cancer patient's probable tumor response to various chemotherapeutic and biologic agents -- providing both sensitivity and resistance information.

"We are very pleased with the results of this study and the correlation between the test results generated using ChemoFX and published response rates for commonly used chemotherapy," said Dr. Holly Gallion, MD, Vice President Medical Affairs, Precision Therapeutics, Inc., "This is a significant step toward ensuring women receive the most effective chemotherapy, early in the treatment process, with limited exposure to therapies that may provide minimal benefit."

About the Study

Tumor specimens were collected from December 1, 2007 to July 15, 2008 from 405 consecutive patients with endometrial carcinoma and were tested in vitro for a response using the ChemoFx assay. Tumors were categorized prospectively as responsive (R), intermediately responsive (IR) or nonresponsive (NR) to each drug or combination of drugs tested. The in vitro response rates were compared to reported response rates from clinical trials.

The International Federation of Gynecology and Obstetrics (FIGO) stage distribution was 171 stage I patients, 32 stage II patients, 106 stage III patients, 57 stage IV patients, 37 recurrent patients, and 2 unknown patients. The assay was successfully completed for 360 (89 percent) cases. The majority of tumors (73 percent) exhibited varying degrees of responsiveness to different drug(s). No significant difference in response rate was observed between primary and recurrent tumors or between stage I/II and III/IV tumors.

In vitro tumor response rates were similar to reported treatment response rates for all treatments except single-agent carboplatin. Investigators concluded that a drug response marker can provide clinically useful information to optimize individual chemotherapy regimens for women with endometrial cancer.

About Precision Therapeutics

Precision Therapeutics is a diagnostics services company dedicated to providing physicians and patients with actionable clinical information to personalize cancer treatments. Precision Therapeutics is a leader in the development and delivery of treatment support tools that assist physicians and benefit cancer patients. For more information visit www.precisiontherapeutics.com, call 800-547-6165 or email info@precisiontherapeutics.com.


'/>"/>
SOURCE Precision Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care
2. Global Creative, Media and Technology Agency LBi Launches Cutting Edge Social Movement for the British Red Cross in Support of Refugee Week
3. Prairie Island Indian Community Supports Fight Against Diabetes Locally and Nationally
4. Concurrent Technologies Corporation Awarded Contract to Support the Centers for Disease Control and Prevention with Readiness Efforts
5. New Virginia Poll: 71 Percent of Voters Strongly Support FDA Regulation of Tobacco Products
6. New Mississippi Poll: Voters Strongly Support FDA Regulation of Tobacco Products
7. Craneware Supports Hospitals Compliance and Upfront Collections with Accurate Estimates
8. Spanish-Speaking OmniPod Customer Support Now Available Around-the-Clock
9. Voters Urged to Support Budding Moves to Include Long Term Care in National Health Reform
10. Kindred Healthcare Supports the Flag and the Sacrifices it Represents
11. Childrens Health Fund Receives $500,000 from the Starr International Foundation to Support South Bronx Homeless Health Care Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... ... Myers Jackson is well known for auctioning homes that people move and flip. ... planet. The luxury home market is alive and well and there are mansions for ... “11 Spyglass Hill Auction will enlighten you on the dynamics of how to market ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... which the endometrial lining of the uterus spreads into the pelvic cavity, ... painful intercourse, painful periods, pelvic pain, or irregular bleeding may have Endometriosis. ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... to its solutions portfolio. ExtraHop delivers an analytics-first approach, layered with machine learning, ... system, from the datacenter to the cloud to the edge. Through the new ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... pediatric dentistry options for its patients on Long Island, New York. , ... well being, and is one of the biggest trends in dentistry today. ...
(Date:5/24/2017)... ... 2017 , ... The CFOs included on this list lead ... the nation and help their organizations navigate the challenges in healthcare today. These ... developing successful hospital and health system strategy. , Becker's Hospital Review has published ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals Inc. ... a clinical-stage pharmaceutical company focused on the development ... the Canadian Intellectual Property Office has granted Oramed ... Administration of Exenatide". The patent covers Oramed,s invention ... GLP-1 is an incretin hormone that stimulates ...
(Date:5/6/2017)... 2017  May is Stroke Awareness Month and Omron ... important methods to prevent a stroke: monitor and manage ... Control and Prevention, undetected and uncontrolled hypertension is a ... global leader in personal heart health technology, recently evolved ... attack and stroke and is advancing a national public ...
(Date:5/4/2017)... and SAN DIEGO , May 4, ... (ACOG) 2017 Annual Clinical and Scientific Meeting— OBP Medical ... medical devices, today announced the launch of a new ... OfficeSPEC and ER-SPEC vaginal specula. Already ... extra-small and extra-large sizes makes OBP Medical,s line of ...
Breaking Medicine Technology: